China Universal Asset Management Company’s CytomX Therapeutics CTMX Stock Holding History

China Universal Asset Management Company’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$242K	Buy	64,647 +9,579	+17%	+$36.6K	0.01%	340
2026 Q1	$259K	Buy	55,068 +27,459	+99%	+$139K	0.02%	330
2025 Q4	$118K	Buy	+27,609	New	+$105K	0.01%	400
2022 Q4	–	Sell	-617	Closed	-$1K	–	414
2022 Q3	$1K	Buy	+617	New	+$950	﹤0.01%	391

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

China Universal Asset Management Company's CTMX Position: Q2 2026 in Review

China Universal Asset Management Company increased its CytomX Therapeutics (CTMX) stake by 17% in Q2 2026, buying an estimated $36.6K and bringing the position to 64,647 shares worth $242K. The position accounts for 0.01% of the portfolio, ranked #340.

China Universal Asset Management Company first reported a position in CTMX in Q3 2022 and has held it in 4 quarters since. The position peaked at $259K in Q1 2026. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

China Universal Asset Management Company held 64,647 shares of CytomX Therapeutics worth $242K as of Q2 2026.
China Universal Asset Management Company bought 9,579 CytomX Therapeutics shares in Q2 2026, an estimated $36.6K.
CytomX Therapeutics made up 0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #340 holding.
China Universal Asset Management Company first reported a position in CytomX Therapeutics in Q3 2022 and has held it in 4 quarters since.
China Universal Asset Management Company's CytomX Therapeutics position peaked at $259K in Q1 2026.
178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.